Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Board of Directors of Rosseti Moscow Region recommended that dividends be paid for 2022

5/24/23 MSRS

RuStore offers foreign applications through the Aptoide platform

5/24/23 VKCO

Segezha Group reported for 3 months of 2023 by IFRS

5/24/23 SGZH

Globaltruck has a new CEO

5/23/23 GTRK

Ozon expands presence in Kazakhstan

5/23/23 OZON

Board of Directors of Kuznetskiy Bank recommended that dividends be paid for 2022

5/23/23 KUZB

Europe's share in Nornickel's revenue decreased to 24%

5/23/23 GMKN

Gazprom's Board of Directors recommends not to pay final dividends for 2022

5/23/23 GAZP

Board of Directors of Gazprom Neft recommended that dividends be paid for 2022

5/23/23 SIBN

Gazprom reported for 2022 by IFRS

5/23/23 GAZP